Previous 10 | Next 10 |
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify . Stocks wrapped up another strong week on a high note, as the Federal Reserve’s new, more tolerant approach to inflation rippled t...
Gainers: Just Energy Group (NYSE: JE ) +35% . More news on: Just Energy Group Inc., Nutanix, Inc., FTS International, Inc., Stocks on the move, Read more ...
Odonate Therapeutics (NASDAQ: ODT ) has priced its public offering of 5,614,036 common shares at a price of $14.25/share, for expected gross proceeds of $80M. More news on: Odonate Therapeutics, Inc., Healthcare stocks news, , Read more ...
Gainers: Cancer Genetics (NASDAQ: CGIX ) +142% . More news on: Cancer Genetics, Inc., iBio, Inc., Sonnet BioTherapeutics Holdings, Inc., Stocks on the move, , Read more ...
Odonate Therapeutics (NASDAQ: ODT ) says that the CONTESSA (Phase 3) trial evaluating lead candidate tesetaxel in metastatic breast cancer (MBC) patients met the primary endpoint of improved Progression-free Survival (PFS), with median PFS of 9.8 months for tesetaxe...
Onconova Therapeutics (NASDAQ: ONTX ) -71% after announcing topline results from Phase 3 INSPIRE trial. More news on: Onconova Therapeutics, Inc., Northern Dynasty Minerals Ltd., Odonate Therapeutics, Inc., Stocks on the move, , Read more ...
CONTESSA Achieved Primary Endpoint – Tesetaxel Plus a Reduced Dose of Capecitabine Significantly Improved Progression-free Survival (PFS) Versus the Approved Dose of Capecitabine Alone (Hazard Ratio=0.716; p=0.003) Median PFS Was 9.8 Months for Tesetaxel Plus a Reduced Dose of C...
Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced that it will hold a conference call on Monday, August 24, 2020 at 8:30 a.m. ET. To partici...
Odonate Therapeutics (NASDAQ: ODT ) : Q2 GAAP EPS of -$1.09 misses by $0.08 . More news on: Odonate Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and six months ended June 30, 2020. As of ...
News, Short Squeeze, Breakout and More Instantly...
Odonate Therapeutics Inc. Company Name:
ODT Stock Symbol:
NASDAQ Market:
Odonate Therapeutics Inc. Website:
Odonate Therapeutics, Inc. (NASDAQ: ODT) today announced that on January 6, 2022 it received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) notifying Odonate that Nasdaq believes that Odonate is a "public shell" pursuant to Listing Rule 5101, and that the c...
ODONATE INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Odonate Therapeutics, Inc. - ODT ODONATE INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, L...
Odonate Therapeutics, Inc. (NASDAQ: ODT) today announced that it will commence a share repurchase plan for up to 20 million shares in order to return capital to stockholders. This action is in connection with the Company’s previously announced decision to discontinue the deve...